Literature DB >> 29707420

PROLACTIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA WHO WERE SWITCHED FROM DAILY TO ONCE-MONTHLY ARIPIPRAZOLE TREATMENT.

Masaru Nakamura1, Takahiko Nagamine1.   

Abstract

Entities:  

Year:  2018        PMID： 29707420      PMCID： PMC5906083     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN： 2158-8333


× No keyword cloud information.
  10 in total

1.  Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.

Authors:  Suresh Mallikaarjun; John M Kane; Patricia Bricmont; Robert McQuade; William Carson; Raymond Sanchez; Robert A Forbes; W Wolfgang Fleischhacker
Journal:  Schizophr Res       Date:  2013-07-23       Impact factor: 4.939

Review 2.  Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.

Authors:  Masaomi Iyo; Shigenori Tadokoro; Nobuhisa Kanahara; Tasuku Hashimoto; Tomihisa Niitsu; Hiroyuki Watanabe; Kenji Hashimoto
Journal:  J Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.153

3.  Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.

Authors:  Akihide Wakamatsu; Kazuo Aoki; Yojiro Sakiyama; Takashi Ohnishi; Makoto Sugita
Journal:  Innov Clin Neurosci       Date:  2013-03

Review 4.  Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.

Authors:  Fuminari Misawa; Taishiro Kishimoto; Katsuhiko Hagi; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2016-08-04       Impact factor: 4.939

5.  Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.

Authors:  Ryosuke Arakawa; Masaki Okumura; Hiroshi Ito; Akihiro Takano; Hidehiko Takahashi; Harumasa Takano; Jun Maeda; Yoshiro Okubo; Tetsuya Suhara
Journal:  J Clin Psychiatry       Date:  2010-02-23       Impact factor: 4.384

6.  Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient.

Authors:  Masaru Nakamura; Yasutaka Fujita; Takahiko Nagamine
Journal:  Asia Pac Psychiatry       Date:  2018-01-03       Impact factor: 2.538

7.  Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.

Authors:  W Wolfgang Fleischhacker; Raymond Sanchez; Pamela P Perry; Na Jin; Timothy Peters-Strickland; Brian R Johnson; Ross A Baker; Anna Eramo; Robert D McQuade; William H Carson; David Walling; John M Kane
Journal:  Br J Psychiatry       Date:  2014-06-12       Impact factor: 9.319

8.  Prolactin Levels After Switching to Paliperidone Palmitate in Patients with Schizophrenia.

Authors:  Masaru Nakamura; Takahiko Nagamine; Goro Sato; Kazue Besho
Journal:  Innov Clin Neurosci       Date:  2016-06-01

9.  Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.

Authors:  Suresh Mallikaarjun; Daniel E Salazar; Steven L Bramer
Journal:  J Clin Pharmacol       Date:  2004-02       Impact factor: 3.126

10.  Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies.

Authors:  Michael Markowitz; Dong-Jing Fu; Bennett Levitan; Srihari Gopal; Ibrahim Turkoz; Larry Alphs
Journal:  Ann Gen Psychiatry       Date:  2013-07-11       Impact factor: 3.455
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.